Protein Classes
Protein Summary
Mediator of programmed cell death (apoptosis). During non-canonical inflammasome activation, cuts CGAS and may play a role in the regulation of antiviral innate immune activation (PubMed:28314590). This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. Overexpression of the active form of this enzyme induces apoptosis in fibroblasts. Max, a central component of the Myc/Max/Mad transcription regulation network important for cell growth, differentiation, and apoptosis, is cleaved by this protein; this process requires Fas-mediated dephosphorylation of Max. The expression of this gene is regulated by interferon-gamma and lipopolysaccharide. Alternatively spliced transcript varian ...more
- ENST00000260315
- ENSP00000260315
- ENSG00000137757
- ENST00000393141
- ENSP00000376849
- ENST00000418434
- ENSP00000398130
- ENST00000444749
- ENSP00000388365
- ENST00000456200
- ENSP00000408455
- ENST00000526056
- ENSP00000436877
- ENST00000531367
- ENSP00000434471
- ICH3
- ICH-3
- ICEREL-III
- ICE(rel)III
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
protein domain | 0.99 | ||
virus perturbation | 0.88 | ||
cell type or tissue | 0.85 | ||
biological process | 0.6 | ||
cell line | 0.56 | ||
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 101.14 (req: < 5)
Gene RIFs: 29 (req: <= 3)
Antibodies: 515 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 101.14 (req: >= 5)
Gene RIFs: 29 (req: > 3)
Antibodies: 515 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 20
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0
Active Ligands (20)
1 – 10 of 20
Pathways (4)
KEGG (1)
PathwayCommons (1)
WikiPathways (2)
Items per page:
1 – 1 of 1
Data Source | Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|---|
KEGG | NOD-like receptor signaling pathway | ||||
Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|
NOD-like receptor signaling pathway | ||||
Gene Ontology Terms (10)
Functions (3)
Components (2)
Processes (5)
Items per page:
10
1 – 3 of 3
GO Term | Evidence | Assigned by | ||
---|---|---|---|---|
Inferred from Direct Assay (IDA) | UniProtKB | |||
Inferred from Biological aspect of Ancestor (IBA) | GO_Central | |||
Traceable Author Statement (TAS) | ProtInc | |||
Protein-Protein Interactions (71)
1 – 10 of 71
CASP4
Family: Enzyme
Novelty: 0.00576072
p_int: 0.999999847
p_ni: 5e-9
p_wrong: 1.48e-7
Score: 0.893
Data Source: BioPlex,STRINGDB
ARHGAP44
Family: Enzyme
Novelty: 0.02469338
p_int: 0.992134868
p_ni: 0.000478228
p_wrong: 0.007386904
Score: 0.345
Data Source: BioPlex,STRINGDB
LACRT
Novelty: 0.04444288
p_int: 0.916240649
p_ni: 0.076839055
p_wrong: 0.006920296
Score: 0.189
Data Source: BioPlex,STRINGDB
NLRP1
Novelty: 0.00548
Score: 0.987
Data Source: STRINGDB
PYCARD
Novelty: 0.00561282
Score: 0.979
Data Source: STRINGDB
NLRP3
Novelty: 0.00042021
Score: 0.976
Data Source: STRINGDB
CARD8
Family: Enzyme
Novelty: 0.00962965
Score: 0.97
Data Source: STRINGDB
AIM2
Novelty: 0.00325294
Score: 0.965
Data Source: STRINGDB
GSDMD
Novelty: 0.01231428
Score: 0.942
Data Source: STRINGDB
CASP1
Family: Enzyme
Novelty: 0.00043112
Score: 0.936
Data Source: STRINGDB
Publication Statistics
PubMed Score 101.14
PubMed score by year
PubTator Score 125.56
PubTator score by year
Amino Acid Sequence
Residue Counts
Sequence
MAEDSGKKKRRKNFEAMFKGILQSGLDNFVINHMLKNNVAGQTSIQTLVPNTDQKSTSVKKDNHKKKTVK
1-70
MLEYLGKDVLHGVFNYLAKHDVLTLKEEEKKKYYDTKIEDKALILVDSLRKNRVAHQMFTQTLLNMDQKI
70-140
TSVKPLLQIEAGPPESAESTNILKLCPREEFLRLCKKNHDEIYPIKKREDRRRLALIICNTKFDHLPARN
140-210
GAHYDIVGMKRLLQGLGYTVVDEKNLTARDMESVLRAFAARPEHKSSDSTFLVLMSHGILEGICGTAHKK
210-280
KKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGEKHGELWVRDSPASLALISSQSSENLEADSVCK
280-350
IHEEKDFIAFCSSTPHNVSWRDRTRGSIFITELITCFQKYSCCCHLMEIFRKVQKSFEVPQAKAQMPTIE
350-420
RATLTRDFYLFPGN
420-434
MAEDSGKKKRRKNFEAMFKGILQSGLDNFVINHMLKNNVAGQTSIQTLVPNTDQKSTSVKKDNHKKKTVKMLEYLGKDVLHGVFNYLAKHDVLTLKEEEKKKYYDTKIEDKALILVDSLRKNRVAHQMFTQTLLNMDQKITSVKPLLQIEAGPPESAESTNILKLCPREEFLRLCKKNHDEIYPIKKREDRRRLALIICNTKFDHLPARNGAHYDIVGMKRLLQGLGYTVVDEKNLTARDMESVLRAFAARPEHKSSDSTFLVLMSHGILEGICGTAHKKKKPDVLLYDTIFQIFNNRNCLSLKDKPKVIIVQACRGEKHGELWVRDSPASLALISSQSSENLEADSVCKIHEEKDFIAFCSSTPHNVSWRDRTRGSIFITELITCFQKYSCCCHLMEIFRKVQKSFEVPQAKAQMPTIERATLTRDFYLFPGN
Find similar targets by: